Mainz Biomed N.V. announced a cooperation agreement with CARE diagnostica Laborreagenzien GmbH to expand the distribution of its ColoAlert test in the German market. This collaboration comes into effect immediately.
CARE diagnostica currently works with over 15 statutory health insurance companies, offering online-based screening concepts using fecal immunochemical tests (FIT). The new agreement will expand this service to include the ColoAlert test for risk groups.
ColoAlert utilizes molecular genetic analysis of biomarkers in stool samples using PCR technology, aiming to increase the detection rate, particularly in the early stages of colorectal cancer. This partnership aligns with the growing demand for personalized screening solutions and enhances Mainz Biomed's market penetration in Germany.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.